Indications
Regranex is indicated, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2.
Composition
- Active substance
- becaplermin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Regranex
- Active substance
- becaplermin
- ATC code
- D03AX06
- Group
- Dermatologicals
- Therapeutic area
- Wound Healing, Skin Ulcer
- Marketing authorisation holder
- Janssen-Cilag International NV
- Status
- Withdrawn
- EU authorisation